Should Research Subjects Be Given Their Genetic Test Results?
By Margaret Lutze,
Guardian Liberty Voice
| 06. 12. 2014
Untitled Document
Should research subjects be given their genetic test results? A paper recently published in The American Journal of Human Genetics considered the ethical issues related to returning genetic testing results to people who have participated in research experiments.
There is a growing number of research projects that use next-generation DNA sequencing to determine the sequence of the DNA nucleotides (ATCGs) in a person’s entire genome. Next-generation sequencing is a new technique that allows DNA sequencing information for an individual to be gathered very quickly. Previously, only certain chosen areas of a person’s genome would be sequenced for a research study due to time and efficiency constraints. Now, however, with the efficiency of next-generation sequencing, it is cost- and time-effective to sequence everything, meaning all the DNA of that person.
The ethical dilemma that results from this is the fact that the research scientist now has information about all of the research subject’s genes, and there may be something in their genetic make-up that would be medically significant for that person. The question is, since the research scientist may now have...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...